Parkin deficiency promotes liver cancer metastasis by TMEFF1 transcription activation via TGF-/Smad2/3 pathway

Parkin (PARK2) deficiency is frequently observed in various cancers and potentially promotes tumor progression. Here, we showed that Parkin expression is downregulated in liver cancer tissues, which correlates with poor patient survival. Parkin deficiency in liver cancer cells promotes migration and metastasis as well as changes in EMT and metastasis markers. A negative correlation exists between TMEFF1 and Parkin expression in liver cancer cells and tumor tissues. Parkin deficiency leads to upregulation of TMEFF1 which promotes migration and metastasis. TMEFF1 transcription is activated by Parkin-induced endogenous TGF-beta production and subsequent phosphorylation of Smad2/3 and its binding to TMEFF1 promotor. TGF-beta inhibitor and TMEFF1 knockdown can reverse shParkin-induced cell migration and changes of EMT markers. Parkin interacts with and promotes the ubiquitin-dependent degradation of HIF-1 alpha/HIF-1 beta and p53, which accounts for the suppression of TGF-beta production. Our data have revealed that Parkin deficiency in cancer leads to the activation of the TGF-beta/Smad2/3 pathway, resulting in the expression of TMEFF1 which promotes cell migration, EMT, and metastasis in liver cancer cells.